Terry Pearson
Chief Tech/Sci/R&D Officer at Siscapa Assay Technologies, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Deborah Rathjen | M | - | 7 years | |
Wilfred A. Jefferies | M | 65 |
Eyam Vaccines & Immunotherapeutics Ltd.
CAVA Healthcare, Inc.
CAVA Healthcare, Inc. Food: Specialty/CandyConsumer Non-Durables CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada. | - |
Adrian P. Wade | M | - |
CAVA Healthcare, Inc.
CAVA Healthcare, Inc. Food: Specialty/CandyConsumer Non-Durables CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada. | 8 years |
Theo Warkentin | M | - |
Eyam Vaccines & Immunotherapeutics Ltd.
CAVA Healthcare, Inc.
CAVA Healthcare, Inc. Food: Specialty/CandyConsumer Non-Durables CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada. | 4 years |
Gustavo Salem | M | 60 |
Siscapa Assay Technologies, Inc.
Siscapa Assay Technologies, Inc. BiotechnologyHealth Technology Siscapa Assay Technologies, Inc. provides products and services for precise quantitation of protein biomarkers, drugs, and drug targets using immuno-affinity mass spectrometry. Siscapa assays are used in clinical diagnostics and pharma R&D for particularly demanding applications, and in biomarker panels to characterize changes in health, disease, and treatment in longitudinal user-collected dried blood microsamples. Siscapa immuno-affinity mass spectrometry assays for targeted protein quantitation can be developed more quickly than typical ELISA immunoassays since they require only a single specific antibody and provide absolute target specificity because of the MS detection. Because Siscapa assays do not interact with one another, these assays can be freely assembled in panels for various applications. The American company was founded by N. Leigh Anderson, who has been the CEO since incorporation. | 10 years |
Ryan M. Thomas | M | - |
Eyam Vaccines & Immunotherapeutics Ltd.
| 4 years |
Jamie Kirwin | F | - |
CAVA Healthcare, Inc.
CAVA Healthcare, Inc. Food: Specialty/CandyConsumer Non-Durables CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada. | 3 years |
Roslyn Ritchie-Derrien | F | 61 |
Eyam Vaccines & Immunotherapeutics Ltd.
CAVA Healthcare, Inc.
CAVA Healthcare, Inc. Food: Specialty/CandyConsumer Non-Durables CAVA Healthcare, Inc. operates as a early stage biotechnology company. The company is headquartered in Surrey, Canada. | 4 years |
N. Anderson | M | 74 |
Siscapa Assay Technologies, Inc.
Siscapa Assay Technologies, Inc. BiotechnologyHealth Technology Siscapa Assay Technologies, Inc. provides products and services for precise quantitation of protein biomarkers, drugs, and drug targets using immuno-affinity mass spectrometry. Siscapa assays are used in clinical diagnostics and pharma R&D for particularly demanding applications, and in biomarker panels to characterize changes in health, disease, and treatment in longitudinal user-collected dried blood microsamples. Siscapa immuno-affinity mass spectrometry assays for targeted protein quantitation can be developed more quickly than typical ELISA immunoassays since they require only a single specific antibody and provide absolute target specificity because of the MS detection. Because Siscapa assays do not interact with one another, these assays can be freely assembled in panels for various applications. The American company was founded by N. Leigh Anderson, who has been the CEO since incorporation. | 13 years |
Reno Pontarollo | M | - |
Eyam Vaccines & Immunotherapeutics Ltd.
| 4 years |
Mei Mei Tian | M | - | 12 years | |
Graeme Dick | M | - | 13 years | |
James E. LaBelle | M | - |
Eyam Vaccines & Immunotherapeutics Ltd.
| 3 years |
Lyle Oberg | M | 63 |
Eyam Vaccines & Immunotherapeutics Ltd.
| - |
Elizabeth Jobes | F | 57 |
Eyam Vaccines & Immunotherapeutics Ltd.
| 3 years |
John S. MacDonald | M | - |
Science Council of British Columbia
| - |
Pamela Lincez | M | - |
Eyam Vaccines & Immunotherapeutics Ltd.
| 3 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
David J. Clark | M | 68 | 8 years | |
Mark Day | M | 52 | 2 years | |
Ronald Erickson | M | 80 | 7 years | |
Mahalakshmi Radhakrishnan | M | - | 1 years | |
Catherine London | F | - | - | |
Judith F. Dalling | F | 69 | 3 years | |
J. Hutchison | M | 68 | 9 years | |
H. Christian Fibiger | M | 80 | 7 years | |
Gregory Gubitz | M | 66 | 5 years | |
Nancy E. Stagliano | M | 57 | 2 years | |
David T. Howard | M | 74 | 1 years | |
Hugh MacNaught | M | - | - | |
Reinhard Gabathuler | M | - | - | |
Karoly Nikolich | M | - | 2 years | |
Craig Dalton Thomas | M | 72 | - | |
Doug Williams | M | - | - | |
George Sanders | M | - | 4 years | |
John Michael Hutchison | M | 80 | 6 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 23 | 65.71% |
Canada | 12 | 34.29% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Terry Pearson
- Personal Network